PaxMedica Inc. Common Sto... (PXMD)

OTC: PXMD · Real-Time Price · USD

0.00

-0.00 (-100.00%)

At close: Mar 18, 2025, 2:54 PM

-100.00% (1D)

Bid	n/a
Market Cap	25.13K
Revenue (ttm)	n/a
Net Income (ttm)	n/a
EPS (ttm)	-2.77
PE Ratio (ttm)	n/a
Forward PE	-0.03
Analyst	n/a

Ask	n/a
Volume	600
Avg. Volume (20D)	8,465
Open	0.00
Previous Close	0.00
Day's Range	0.00 - 0.00
52-Week Range	0.00 - 1.19
Beta	-0.56

About PXMD

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomi...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 26, 2022

Employees 6

Stock Exchange OTC

Ticker Symbol PXMD

Website https://www.paxmedica.com

Full Company Profile

News

1 year ago · pennystocks.com

Choosing Unknown Penny Stocks, 3 Top Tips

Penny stocks represent an exciting opportunity for investors looking to expand their portfolios with potentially lucrative, yet cost-effective options. Typically trading below five dollars per share, ...

1 year ago · invezz.com

Why is PaxMedica (PXMD) stock surging today?

PaxMedica (NASDAQ: PXMD) has surged by 92.7% so far on Friday, reflecting the market's positive reaction to the company's announcement of significant progress in its drug development efforts.

1 year ago · investorplace.com

Why Is PaxMedica (PXMD) Stock Up 93% Today?

PaxMedica (NASDAQ: PXMD ) stock is rocketing higher on Friday after the clinical-stage biopharmaceutical company reached a key milestone in drug development. The big news here is the company securing ...

Advertisement